800
Participants
Start Date
May 11, 2017
Primary Completion Date
October 31, 2025
Study Completion Date
January 30, 2026
INTERCEPT Blood System for Red Blood Cells
The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5 or SAG-M for non-US sites. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
Conventional (Control)
Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
ACTIVE_NOT_RECRUITING
Virginia Commonwealth University, Richmond
RECRUITING
Grady Health System, Atlanta
RECRUITING
CHOA (Children's Healthcare of Atlanta), Atlanta
ACTIVE_NOT_RECRUITING
Mayo Clinic Jacksonville, Jacksonville
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
Baylor St. Luke's Medical Center, Houston
RECRUITING
Phoenix Children's Hospital (PCH), Phoenix
RECRUITING
C4TKs (Cure 4 The Kids), Las Vegas
ACTIVE_NOT_RECRUITING
Yale University, New Haven
ACTIVE_NOT_RECRUITING
Menonita General Hospital, Aibonito
ACTIVE_NOT_RECRUITING
HIMA San Pablo Hospital, Caguas
ACTIVE_NOT_RECRUITING
San Juan Bautista School of Medicine Clinical Research Unit, Caguas
Lead Sponsor
Cerus Corporation
INDUSTRY